$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Lactobacillus acidophilus BK13 and Lactobacillus paracasei BK57 균주가 생산한 항균물질의 anti-Helicobacter pylori 활성 및 위장상피세포에 대한 세포독성 평가
Evaluation of the anti-Helicobacter pylori and cytotoxic properties of the antimicrobial substances from Lactobacillus acidophilus BK13 and Lactobacillus paracasei BK57 원문보기

Korean journal of microbiology = 미생물학회지, v.51 no.2, 2015년, pp.156 - 168  

임은서 (동명대학교 식품영양학과)

초록
AI-Helper 아이콘AI-Helper

Lactobacillus acidophilus BK13과 Lactobacillus paracasei BK57 균주로부터 얻은 세포, 배양상등액 및 박테리오신 용액의 anti-Helicobacter pylori 활성과 위장상피세포에 대한 세포독성을 평가하였다. 실험균주를 MRS 배지 상에서 30시간 배양한 결과, L. acidophilus BK57 ($126.8{\pm}7.9mM$) 보다 L. paracasei BK57 ($155.9{\pm}7.9mM$)가 더 많은 양의 유산을 생산하였다. 또한, BK13 균주의 최대 박테리오신 활성(128 AU/ml)은 $37^{\circ}C$에서 30시간 배양 후 관찰되었으나, 이는 BK57의 활성(256 AU/ml) 보다는 낮았다. BK13 및 BK57 균주의 살아있는 세포를 H. pylori와 혼합 배양한 결과, 유산균의 초기균수에 의존하여 H. pylori의 저해효과가 나타났다. 게다가 BK13과 BK57로부터 얻은 배양상등액과 박테리오신은 H. pylori의 성장을 억제할 뿐만 아니라 위장상피세포에 대한 부착력과 urease 활성도 저해하였다. 한편, 이러한 균주들이 생산한 유산은 위암세포에 대한 세포독성 효과가 대조구보다 유의한 수준으로 높게 나타났다. 따라서 BK13과 BK57 균주의 항균물질은 위장질환의 원인균인 H. pylori를 저해시키는데 효과적이므로 이들 유산균은 H. pylori 감염으로부터 위장을 보호하는데 유용할 것으로 사료된다.

Abstract AI-Helper 아이콘AI-Helper

The objective of this study is to investigate the anti-Helicobacter pylori and anti-cancer activities of the live cells (LC), cell-free culture supernatants (CFCS), and bacteriocin solution (BS) obtained from Lactobacillus acidophilus BK13 and Lactobacillus paracasei BK57 strains. After incubation f...

주제어

참고문헌 (53)

  1. Aiba, Y., Suzuki, N., Kabir, A.M., Takagi, A., and Koga, Y. 1998. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am. J. Gastroenterol. 93, 2097-2101. 

  2. Aslim, B., Onbasili, D., and Yuksekdag, Z. 2011. Determination of lactic acid production and antagonistic activity against Helicobacter pylori in L. delbrueckii subsp. bulgaricus and S. thermophilus strains. Kafkas Univ. Vet. Fak. Derg. 17, 609-614. 

  3. Atanassova, M., Choiset, Y., Dalgalarrondo, M., Chobert, J.M., Dousset, X., Ivanova, I., and Haertle, T. 2003. Isolation and partial biochemical characterization of a proteinaceouos antibacteria and anti-yeast compound produced by Lactobacillus paracasei subsp. paracasei strain M3. Int. J. Food Microbiol. 87, 63-73. 

  4. Boirivant, M. and Strober, W. 2007. The mechanisms of action of probiotics. Curr. Opin. Gastroenterol. 23, 679-692. 

  5. Boyanova, L., Stephanova-Kondratenko, M., and Mitov, I. 2009. Anti-Helicobacter pylori activity of Lactobacillus delbrueckii subsp. bulgaricus strains: preliminary report. Lett. Appl. Microbiol. 48, 579-584. 

  6. Brown, L.M. 2000. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol. Rev. 22, 283-297. 

  7. Brul, S. and Coote, P. 1999. Preservative agents in foods: mode of action and microbiol resistance mechanisms. Int. J. Food Microbiol. 50, 1-17. 

  8. Cave, D.R. 1997. How is Helicobacter pylori transmitted? Gasroenterology 113, S9-S14. 

  9. Cellini, L. and Donelli, G. 2000. Virulence factors of Helicobacter pylori. Microb. Ecol. Health. D. 2, 259-262. 

  10. Chen, X., Liu, X.M., Tian, F., Zhang, Q., Zhang, H.P., Zhang, H., and Chen, W. 2011. Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. J. Food Sci. 71, M9-M14. 

  11. Coconnier, M.H,, Lievin, V., Hemery, E., and Servin, A. 1998. Antagonistic activity against Helicobacter pylori infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl. Environ. Microbiol. 64, 4573-4580 

  12. De Vuyst, L. and Leroy, F. 2007. Bacteriocins from lactic acid bacteria: Production, purification, and food applications. J. Mol. Microbiol. Biotechnol. 13, 194-199. 

  13. De Vuyst, L., Makras, L., Avonts, L., Holo, H., Yi, Q., Servin, A., Fayol-Messaoudi, D., Gerger, C., Zoumpopoulou, G., Tsakalidou, E., et al. 2004. Antimicrobial potential of probiotic or potentially probiotic lactic acid bacteria, the first results of the international European research project PROPATH of the PROEUHEALTH cluster. Microb. Ecol. Health. D. 16, 125-130. 

  14. Egan, B.J., Katicic, M., O'onnor, H.J., and O'orain, C.A. 2007. Treatment of Helicobacter pylori. Helicobacter 12, 31-37. 

  15. Fichera, G.A. and Giese, G. 1994. Non-immunologically-mediated cytotoxicity of Lactobacillus casei and its derivative peptidoglycan against tumor cell lines. Cancer Lett. 85, 93-103. 

  16. Genta, R.M., Gurer, I.E., Graham. D.Y., Krishnan, B., Sequra, A.M., Gutierrez, O., Kim, J.G., and Burchette, J.L. 1996. Adherence of Helicobacter pylori to areas of incomplete intestinal metaplasia in the gatric mucosa. Gastroenterology 111, 1206-1211. 

  17. Gotteland, M., Brunser, O., and Cruchet, S. 2006. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol. Ther. 23, 1077-1086. 

  18. Hamilton-Miller, J.M.T. 2003. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int. J. Antimicrob. Agents 22, 360-366. 

  19. Hemaiswarya, S., Raja, R., Ravikumar, R., and Carvalho, I.S. 2013. Mechanism of action of probiotics. Braz. Arch. Biol. Technol. 56, 113-119. 

  20. Hole, H., Nilssen, O., and Nes, I.F. 1991. Lactococcin A, a new bacteriocin from Lactococcus lactis subsp. cremoris: Isolation and characterization of the protein and its gene. J. Bacteriol. 173, 3879-3887. 

  21. Joo, N.E., Ritchie, K., Kamarajan, P., Miao, D., and Kapila, Y.L. 2012. Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1. Cancer Med. 1, 295-305. 

  22. Kaur, B., Balgir, P.P., Mittu, B., Kumar, B., and Garg, N. 2013. Biomedical applications of fermenticin HV6b isolated from Lactobacillus feremtum HV6b MTCC 10770. BioMed Res. Int. 2013, 1-8. 

  23. Kim, T.S., Hur, J.W., Yu, M.A., Cheigh, C.I., Kim, K.N., Hwang, J.K., and Pyun, Y.R. 2003. Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. J. Food Prot. 66, 3-12. 

  24. Klaenhammer, T.R. 1988. Bacteirocins of lactic acid bacteria. Biochimie 70, 337-349. 

  25. Kusters, J.G., Van Vliet, A.H.M., and Kuipers, E.J. 2006. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 19, 449-490. 

  26. Lesbros-Pantoflickova, D., Corthesy-Theulaz, I., and Blum, A.L. 2007. Helicobacter pylori and probiotics. J. Nutr. 137, 812S-818S. 

  27. Lim, S.M. 2014. Anti-Helicobacter pylori activity of antimicrobial substances produced by lactic acid bacteria isolated from Baikkimchi. J. Kor. Soc. Appl. Biol. Chem. 57, 621-630. 

  28. Lin, W.H., Lin, C.K., Sheu, S.J., Hwang, C.F., Ye, W.T., Hwang, W.Z., and Tsen, H.Y. 2009. Antagonistic activity of spent culture supernatants of lactic acid bacteria against Helicobacter pylori growth and infection in human gastric epithelial AGS cells. J. Food Sci. 74, M225-M230. 

  29. Lorca, G.L., Wadstrom, T., Valdez, G.F., and Ljungh, A. 2001. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr. Microbiol. 42, 39-44. 

  30. Luo, Y.Q., Teng, J.B., Pan, B.R., and Zhang, X.Y. 1999. Liver disease and Helicobacter. World J. Gastroenterol. 5, 334-338. 

  31. Manjunath, N. and Ranganathan, B. 1989. A cytotoxic substance produced by a wild culture of Lactobacillus casei D-34 against tumor cells. Indian J. Exp. Biol. 27, 141-145. 

  32. Michetti, P., Dorta, G., Wiesel, P.H., Brassart, D., Verdu, E., Herranz, M., Felley, C., Porta, N., Felley, C., Porta, N., et al. 1999. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 60, 203-209. 

  33. Midolo, P.D., Lambert, J.R., Hull, R., Luo, F., and Grayson, M.L. 1995. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J. Appl. Bacteriol. 79, 475-479. 

  34. Moll, G.N., Konings, W.N., and Driessen, A.J.M. 1999. Bacteriocins: mechanism of membrane insertion and pore formation. Antonie van Leeuwenhoek 76, 185-198. 

  35. Oelschlaeger, T.A. 2010. Mechanisms of probiotic actions - A review. Int. J. Med. Microbiol. 300, 57-62. 

  36. Pacifico, L., Osborn, J.F., Bonci, E., Romaggioli, S., Baldini, R., and Chiesa, C. 2014. Probiotics for the treatment of Helicobacter pylori infection in children. World J. Gastroenterol. 20, 673-683. 

  37. Powell, J.E., Witthuhn, R.C., Todorov, D.S., and Dicks, L.M.T. 2007. Characterization of bacteriocin ST8KF produced by a kefir isolate Lactobacillus planatrum ST8KF. Int. Dairy J. 17, 190-198. 

  38. Rafter, J. 2002. Lactic acid bacteria and cancer: mechanistic perspective. Br. J. Nutr. 88, S89-S94. 

  39. Sadeghi-Aliabadi, H., Mohammadi, F., Fazeli, H., and Mirlohi, M. 2014. Effects of Lactobacillus planatrum A7 with probiotic potential on colon cancer and normal cells proliferation in comparison with a commercial strain. Iran J. Basic Med. Sci. 17, 815-819. 

  40. Savadogo, A., Ouattara, C.A.T., Bassole, I.H.N., and Traore, S.A. 2006. Bacteriocins and lactic acid bacteria - a minireview. Afr. J. Biotechnol. 5, 678-683. 

  41. Servin, A.L. and Coconnier, M.H. 2003. Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. Best Pract. Res. Cl. Ga. 17, 741-754. 

  42. Settanni, L., Valmorri, S., Suzzi, G., and Corsetti, A. 2008. The role of environmental factors and medium composition on bacteriocin like inhibitory substances (BLIS) production by Enterococcus mundtii strains. Food Microbiol. 25, 722-728. 

  43. Sevda, E.R., Koparal, A.T., and Kivang, M. 2015. Cytotoxic effects of various lactic acid bacteria on Caco-2 cells. Turk. J. Biol. 39, 23-30. 

  44. Sgouras, D., Maragkoudakis, P., Petraki, K., Martinez-Gonzalez, B., Eriotou, E., Michopoulos, S., Kalantzopoulos, G., Tsakalidou, E., and Mentis, A. 2004. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl. Environ. Microbiol. 70, 518-526. 

  45. Shaikh, F., Abhinand, P.A., and Ragunath, P.K. 2012. Identification and characterization of Lactobacillus salavarius bacteriocins and its relevance in cancer therapeutics. Bioinformation 8, 589-594. 

  46. Sutton, P. 2001. Helicobacter pylori vaccines and mechanisms of effective immunity: Is mucus the key? Immunol. Cell Biol. 79, 67-73. 

  47. Todorov, S.D. and Dicks, L.M. 2005. Optimization of bacteriocin ST311LD production by Enterococcus faecium ST311LD, isolated from spoiled black olives. J. Microbiol. 43, 370-374. 

  48. Tsai, C.C., Huang, L.F., Lin, C.C., and Tsen, H.Y. 2004. Antagonistic activity against Helicobacter pylori infection in vitro by a strain of Enterococcus faecium TM39. Int. J. Food Microbiol. 96, 1-12. 

  49. Wang, K.Y., Li, S.N., Kiu, C.S., Perng, D.S., Su, Y.C., Wu, D.C., Jan, C.M., Lai, C.H., Wang, T.N., and Wang, W.M. 2004. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am. J. Clin. Nutr. 80, 737-741. 

  50. Wang, G., Zhao, Y., Tian, F., Jin, X., Chen, H., Liu, X., Zhang, Q., Zhao, J., Chen, Y., Zhang, H., et al. 2014. Screening of adhesive lactobacilli with antagonistic activity against Campylobacter jejuni. Food Control 44, 49-57. 

  51. Wee, Y.J., Kim, J.N., and Ryu, H.W. 2006. Biotechnological production of lactic acid and its recent applications. Food Technol. Biotechnol. 44, 163-172. 

  52. Yoon, Y.H. and Won, B.R. 2002. Antagonism against Helicobacter pylori and proteolysis of Lactobacillus helveticus CU631 and strain identification. Asian-Aust J. Anim. Sci. 15, 1057-1065. 

  53. Zheng, H., Shah, P.K., and Audus, K.L. 1996. Evaluation of antiulcer agents with a human adenocarcinoma cell line (AGS). Int. J. Pharm. 129, 103-112. 

저자의 다른 논문 :

관련 콘텐츠

오픈액세스(OA) 유형

BRONZE

출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로